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Abstract
Treatment with beta-blockers is characterized by inferior reduction of central versus peripheral blood pressure. We examined
changes in blood pressure, cardiac function, and vascular resistance after 3 weeks of bisoprolol treatment (5 mg/day) during
passive head-up tilt in 16 never-treated Caucasian males with grade I–II primary hypertension. A double-blind, randomized,
placebo-controlled cross-over design was applied, and hemodynamics were recorded using continuous tonometric pulse
wave analysis and whole-body impedance cardiography. Bisoprolol decreased blood pressure in the aorta (~8/10 mmHg, p ≤
0.032) and radial artery (~10/9 mmHg, p ≤ 0.037), but upright aortic systolic blood pressure was not signiﬁcantly reduced
(p= 0.085). Bisoprolol reduced heart rate and left cardiac work, and increased subendocardial viability index in supine and
upright positions (p ≤ 0.044 for all). Bisoprolol increased stroke volume in the supine (~11 ml, p= 0.02) but not in the
upright position, while only upright (~1 l/min, p= 0.007) but not supine cardiac output was reduced. Upright elevation in
systemic vascular resistance was increased 2.7-fold (p= 0.002), while upright pulse pressure ampliﬁcation was decreased by
~20% (p= 0.002) after bisoprolol. Aortic augmentation index, augmentation pressure, and pulse pressure were not changed
in the supine position but were increased in the upright position (from 9% to 17%, 3–6 mmHg, and 30–34 mmHg,
respectively, p ≤ 0.016 for all). In conclusion, although bisoprolol treatment reduced peripheral blood pressure, central
systolic blood pressure in the upright position was not decreased. Importantly, the harmful inﬂuences of bisoprolol on central
pulse pressure and pressure wave reﬂection were manifested in the upright position.
Introduction
The use of beta-adrenoceptor blockers (beta-blockers) as
ﬁrst line treatment for hypertension has declined in recent
years due to inferior efﬁcacy in the prevention of cardio-
vascular events when compared with vasodilatory anti-
hypertensive agents [1–3]. One of the reasons for this is the
lesser decrease of central than peripheral blood pressure
(BP) during beta-blockade [4]. Still, beta-blockers remain
the ﬁrst-line therapy in patients with heart failure or recent
myocardial infarction [5]. The pathophysiological mechan-
ism for the inferior reduction in central BP with beta-
blockers could be the longer ejection period during slower
heart rate which allows the reﬂected wave to arrive during
systole and therefore increase the systolic BP [6].
Augmentation index (AIx) is delineated as the proportion
of the reﬂected pressure wave (augmentation pressure, AP)
to pulse pressure (PP). It has been applied as a surrogate
measure of arterial stiffness, but it is mainly a measure of
wave reﬂections [7] that is also inﬂuenced by systemic
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vascular resistance (SVR) [8]. The position of AIx as an
independent predictor of cardiovascular events is still con-
troversial [9]. Taking into account the aforementioned
pathophysiology it can be readily understood why a bene-
ﬁcial effect of beta-blockers on AIx has not been demon-
strated [10, 11].
Ampliﬁcation of PP is deﬁned as the ratio of peripheral
PP to central PP, and due to this phenomenon PP in per-
ipheral arteries is higher than in central arteries [12]. Beta-
blockers have been shown to decrease PP ampliﬁcation
[11], and this can be considered to reﬂect a reduction of
central BP inferior to that of peripheral BP.
During orthostatic challenge, SVR and heart rate increase
while cardiac output (CO) decreases [13]. In addition, AIx
decreases in the upright position but remains constantly
higher in hypertensive than normotensive subjects [14]. The
wave reﬂections in the arterial tree are inﬂuenced by the
time of the systolic ejection, heart rate, arterial stiffness,
arterial branching, and SVR [8]. Beta-blocker therapy has
profound effects on the regulation of heart rate and CO [11,
15]. In spite of the widespread use of these drugs, the effect
of beta-blockers on central BP in the upright position
remains unknown. Such information is very relevant, as
signiﬁcant proportion of the human daytime activity is
performed in the upright position. To test the hypothesis
whether the effects of beta-blocker treatment on central
wave reﬂections and BP are accentuated in the upright
position, we examined non-invasive hemodynamics in
middle-aged men with never-treated grade I to grade II




The study population of 16 non-smoking men with never-
treated grade I to grade II essential hypertension was
recruited via newspaper announcements (n= 14) and from
occupational health care clinics (n= 2) [11]. The age range
for possible inclusion in the study was 18–55 years, and the
age range of the included subjects was 39–55 years. The
deﬁnition of grade I to grade II hypertension was systolic
ofﬁce BP ranging from 140 to 180 mmHg, and diastolic BP
ranging from 90 to 109 mmHg, according to the European
evidence-based clinical guidelines [16].
All volunteers were interviewed and examined by a
physician. Medical history, lifestyle variables, and status
were documented, including BP measurements in the ofﬁce
(seated position, two brachial BP measurements using a
sphygmomanometer, mean value recorded). Smoking was
calculated as pack-years and smoking status was evaluated
as current smoker, non-smoker, or ex-smoker. The time
since smoking cessation in ex-smokers was recorded in
years. Alcohol use was assessed as average ingestion of
standard drinks (~12 g of absolute alcohol) during 1 week.
The amount of exercise was the number of ≥30 min exer-
cise sessions per week that caused shortness of breath or
sweating, as reported by the participants. Routine laboratory
tests were taken [16]. A total of 24 subjects were examined
and eight subjects were excluded on the basis of the fol-
lowing exclusion criteria: use of BP-lowering medication,
secondary hypertension, BMI >35 kg/m2, current smoking,
high consumption of alcohol (>24 restaurant doses/week),
heart rate lower than 50 beats/min at physical examination,
previous diagnosis of a heart disease, diabetes mellitus,
disease of cerebrovascular or peripheral arteries, and pul-
monary disorder.
Written informed consent of participation in the study
was signed by all subjects. The ethics committee of Tam-
pere University Hospital approved the study (investigation
number R09103M) that conformed to the Declaration of
Helsinki and was registered at ClinicalTrials.gov
(NCT01742702).
Study design and research drugs
This randomized, double-blinded cross-over study consisted
of three 3-week periods (Fig. 1). The subjects were rando-
mized into two groups that determined the order of the given
treatments. The pharmacy of Tampere University Hospital,
which was in no way involved in the examination of the study
subjects, performed the randomization in blocks of four par-
ticipants. During the ﬁrst and third 3-week periods the subjects
were given either bisoprolol or placebo once daily. The middle
3-week period was a wash-out phase so that no medications
were given. The applied 5mg daily dose of bisoprolol has
been reported to signiﬁcantly lower BP in Finnish men during
a 24-h ambulatory BP registration [17]. The calculation of the
sample size was based on the hypothesis that bisoprolol 5mg
daily will reduce diastolic BP ≥ 6mmHg with a standard
Fig. 1 Study design. Sixteen male subjects were given bisoprolol or
placebo for 3 weeks in a randomized, double-blind, cross-over study.
A 3-week wash-out period took place between the treatment periods.
Non-invasive hemodynamic measurements were carried out at the end
of the treatment periods
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deviation (SD) of about 6 mmHg [18]. According to this
calculation, ≥13 subjects were required to gain a statistical
power of 90% (two-sided alpha= 0.05), and therefore alto-
gether 16 subjects were recruited.
Hemodynamic measurements
Simultaneous recordings using whole-body impedance
cardiography and radial pulse wave analysis were per-
formed at the end of the ﬁrst and third 3-week periods in a
research laboratory by a trained research nurse (Fig. 1)
[13, 14]. Study subjects were asked to refrain from products
containing caffeine, smoking, and heavy meals for ≥4 h, and
from alcohol consumption for ≥24 h prior to the recordings.
During ~10 min supine rest before the measurements,
electrodes for impedance cardiography were placed on the
body surface, a tonometric sensor for pulse wave analysis
was placed on the left wrist over the radial artery, and a
brachial BP cuff was attached to the right upper arm for BP
calibration. The left arm with the tonometric sensor was
abducted to 90° in a support, holding the wrist steady at the
level of the heart during the measurements. Beat-to-beat
hemodynamics were captured continuously for 10 min
(5 min supine, 5 min upright).
Pulse wave analysis and whole-body impedance
cardiography
A tonometric sensor with automatic adjustment (Colin BP-
508T®, Colin Medical Instruments Corp., USA) was
applied to record radial BP and pulse wave form con-
tinuously, and the BP signal was calibrated at ~2.5 min
intervals by use of the brachial cuff in the contralateral arm
[13, 14]. The aortic pulse wave form was derived from the
radial pulse wave using a validated generalized transfer
function [19] by means of SphygmoCor® pulse wave
monitoring (PWMx system, AtCor Medical, Australia). AIx
(augmented pressure/PP*100%), AIx adjusted to heart rate
75/min (AIx@75), and Buckberg subendocardial viability
ratio [20] were calculated from the aortic pulse wave with
the SphygmoCor software.
Beat-to-beat heart rate, stroke volume, and CO was
determined by the use of whole-body impedance cardio-
graphy (CircMon®, JR Medical Ltd., Tallinn, Estonia) [21].
To calculate SVR, the BP measurement from the radial
tonometric sensor and CO by the CircMon® were used.
SVR was normalized to the surface area of the body (SVR
index, SVRI). With the recordings using CircMon®, stroke
volume values correlate well with three-dimensional echo-
cardiography (r= 0.781, bias 4.1 ml, 95% CI −2.2 to 10.4)
[22], and CO measurements correlate well with values
obtained by the thermodilution method (bias 0.00 l/min,
95% CI −0.26 to 0.26) and the direct oxygen Fick method
(bias −0.32 l/min, 95% CI −0.69 to 0.05) [21]. Left cardiac
work index (LCWI) values were calculated using the for-
mula 0.0143*(mean aortic pressure−pulmonary artery
occlusion pressure)*cardiac index, which was derived by
the equation presented by Gorlin et al. [23]. Pulmonary
artery occlusion pressure value was presumed normal
(6 mmHg) and 0.0143 was the combined factor used to
convert pressure from mmHg to cmH2O, volume to density
of blood (kilograms per liter) and centimeters to meters.
Laboratory analyses
Morning samples of blood and urine were obtained after
~12 h of fasting. The concentrations of sodium, potassium,
creatinine, glucose, triglyceride, and total, high-density, and
low-density lipoprotein (HDL and LDL, respectively) cho-
lesterol in plasma were analyzed using Cobas Integra 700/
800 (F. Hoffmann-Laroche Ltd., Basel, Switzerland) or
Cobas6000, module c501 (Roche Diagnostics, Basel,
Switzerland), and blood cell count by ADVIA 120 or 2120
(Bayer Health Care, Tarrytown, NY, USA). Urine dipstick
analysis was performed using an automated refractometer
(Siemens Clinitec Atlas or Advantus, Siemens Healthcare
GmbH, Erlangen, Germany). GFR was calculated with the
CKD-EPI creatinine-cystatin C—formula [24].
Statistical analyses
Statistical analyses were performed using ANOVA for
repeated measures to test differences between groups and
interaction between time and group. Differences in changes
of a variable were compared with paired samples t-test.
p-Values < 0.05 were considered signiﬁcant. The Shapiro–
Wilk test was used to test that the hemodynamic variables
were normally distributed and the equality of the variances
was assessed with Levene’s test. In the ﬁgures the variables
are depicted as means and standard error of means (SEM)
for every minute of the 10 min recording period. The
3-week wash-out period between bisoprolol and placebo
treatments was considered long enough to prevent any
carryover effect on the placebo treatment phase, since the
half-life of bisoprolol ranges from 10 to 12 h while the full
treatment effect is attained within 2 weeks [25]. IBM SPSS




Every subject completed the study protocol, and their demo-
graphic data are presented as means and SDs in Table 1. The
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age range of the subjects was 39–55 years. There were no
active smokers but seven subjects were ex-smokers with an
average time from smoking cessation of 13 years [95% con-
ﬁdence intervals (CI) 7.7, 18.7]. Average alcohol consumption
(self-reported) was 5.2 standard doses [2.7, 7.8] (each con-
taining 12 g of alcohol) and frequency of physical exercise
sessions 2.7 times per week [1.9, 3.4] (one session ≥ 30min).
According to Cornell’s voltage criteria (RaVL+ SV3 >
28mm) two of the subjects had left ventricular hypertrophy.
Urine dipstick analyses showed no proteinuria or hematuria
while average blood cell counts, and concentrations of sodium,
potassium, and fasting plasma glucose were within the normal
reference values. One subject had a small elevation in
plasma creatinine concentration (113 μmol/L, corresponding
estimated glomerular ﬁltration rate 70mL/min/1.73m2). The
ranges of plasma lipid values were as follows: total
cholesterol 3.7–6.4mmol/L, LDL cholesterol 2.1–4.5mmol/L,
HDL cholesterol 0.9–2.0mmol/L, and triglycerides
0.52–2.4mmol/L (Table 1).
The medications in regular use by the study participants
were statin therapy for hypercholesterolemia (n= 2),
selective serotonin reuptake inhibitors for depression (n=
2), and thyroxine treatment for hypothyroidism with a
steady euthyroid state (n= 1). In addition, gastro-
esophageal reﬂux had been diagnosed in two subjects, but
they did not need any regular medications.
Hemodynamic measurements
In the supine position radial systolic BP was 10mmHg
[4.8, 15.1] and diastolic BP 9mmHg [3.8, 13.9] lower, and
aortic systolic BP 8mmHg [2.7, 12.9] and diastolic BP 9
mmHg [4.3, 14.5] lower during bisoprolol than during pla-
cebo. In the upright position bisoprolol treatment reduced
radial systolic BP by 10mmHg [4.0, 15.0], diastolic BP
by 10mmHg [6.2,13.8], and aortic diastolic by 10mmHg
[6.6, 14.1] (Fig. 2a–d), but contrary to the supine position,
aortic systolic BP was not signiﬁcantly reduced (p= 0.085).
Bisoprolol reduced heart rate in both supine (−11 beats/
min [−7.9, −14,7]) and upright (−16 beats/min [−12,
−20]) positions (Fig. 3a), while the decrease in heart rate
was signiﬁcantly greater upright than supine (−5 beats/min
[2.8, 7.4], p < 0.001). Ejection duration was prolonged in
supine (+20 ms [12.4, 26.7]) and upright (+23 ms [15.6,
30.4]) positions with bisoprolol (Fig. 3b). SEVR increased
both supine (+25 percentage points [14.0, 36.1]) and
upright (+31 percentage points [21.5, 41.0]), while LCWI
was reduced in supine (−0.7 kg*m/m2 [−0.26, −1.1]) and
upright (−1 kg*m/m2 [−0.65,−1.1]) positions with biso-
prolol when compared with placebo (Fig. 3c, d).
Stroke volume was signiﬁcantly higher with bisoprolol in
the supine position (+12 [5.5, 17.5] ml) but not during the
head-up tilt (Fig. 4a), whereas CO was not changed in the
supine position but was signiﬁcantly lower during the
upright position (−1.1 L/min [−0.7, −1.5], Fig. 4b). PP
ampliﬁcation was not changed with bisoprolol in the
supine position, but was reduced (−19 percentage points
[−13, −25]) in the upright position (Fig. 4c). When ana-
lyzed using ANOVA for repeated measures, neither supine
nor upright SVRI was signiﬁcantly different from placebo
during bisoprolol. However, a signiﬁcant time interaction
was observed, and the upright increase in SVRI was 2.7-
fold higher after bisoprolol when compared with placebo
(634 vs. 233 dyn*s/cm5*m2, p= 0.003) (Fig. 4d).
While there were no changes in aortic PP or AP in supine
measurements, upright aortic PP was increased+4 mmHg
[1.7, 7.1] and aortic AP +3 mmHg [1.9, 4.3] with bisoprolol
(Fig. 5a, c). AIx remained unchanged in supine position,
but was signiﬁcantly higher (+7.8 percentage points
[4.8, 10.6]) upright with bisoprolol than with placebo
Fig. 5b). The heart rate-related AIx@75 was not changed
during bisoprolol treatment either supine (p= 0.368) or
upright (p= 0.418) (not shown). No difference in forward
wave amplitude between the bisoprolol and placebo treat-
ments was found (Fig. 5d). Radial PP was unchanged
during bisoprolol both supine (p= 0.6) and upright (p=
0.8) (not shown).
Table 1 Demographic and laboratory data (n= 16)
Variable Mean SD
Age, years 48.4 5.5
Weight, kg 92.5 11.7
Height, cm 180 5.8
Body mass index, kg/m² 28.6 3.4
Waist circumference, cm 103 9.3
Ofﬁce BP at screening
Systolic BP, mmHg 149 9.6
Diastolic BP, mmHg 99 4.4
Heart rate, beats/min 67 10.8
Laboratory values
Hemoglobin, g/L 153 8.8
Potassium, mmol/L 3.9 0.3
Sodium, mmol/L 141 1.5
Creatinine, μmol/L 82 12.6
Cystatin-C, mg/L 0.89 0.09
Calcium (total), mmol/L 2.33 0.13
Total cholesterol, mmol/L 5.1 0.8
HDL-cholesterol, mmol/L 1.3 0.3
LDL-cholesterol, mmol/L 3.2 0.8
Triglycerides, mmol/L 1.4 0.6
Fasting plasma glucose, mmol/L 5.6 0.4
Estimated GFR, ml/min/1.73 m2 95.8 10.7
BP blood pressure, GFR glomerular ﬁltration rate estimated using the
CKD-EPI-Creatinine-cystatin-C formula [23]
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Discussion
In this randomized, placebo-controlled double-blind cross-
over study, non-invasive evaluation of hemodynamics was
carried out in men with mild to moderate primary hyper-
tension during non-vasodilating beta-blocker therapy. The
results show that bisoprolol did not lower central systolic
BP in the upright position although it was efﬁcient in
reducing peripheral BP. Moreover, the harmful inﬂuences
of bisoprolol on central PP and wave reﬂection were
uncovered in the upright position. This emphasizes the
inﬂuence of body posture on the hemodynamic changes
induced by beta-blocker therapy. The supine hemodynamics
and home BP measurements of the present study subjects
were previously reported [11], and the observed reductions
in heart rate and BP correlate well with former results
concerning bisoprolol treatment [17], indicating good
adherence to the medication.
Although the position of beta-blockers in the treatment of
essential hypertension has changed, they remain a mainstay
of pharmacotherapy after myocardial infarction. We
observed a decrease in LCWI, indicating reduced workload
of the left ventricle during bisoprolol therapy, and an
increase in SEVR that reﬂects an improved ratio between
myocardial oxygen supply and demand. These hemody-
namic changes can explain the antianginal effect of beta-
blockers.
During orthostatic challenge, blood pools in the lower
extremities resulting in a decrease in venous return to the
heart. As compensatory mechanisms SVR and heart rate
increase to maintain the level of BP. Despite this adaptation,
CO usually decreases, but there is signiﬁcant inter-
individual variation in the magnitude of these changes
[26]. Of note, the phenotype of the hemodynamic response
to upright posture seems rather persistent over time [27].
Heart rate reduction is a typical effect of non-vasodilating
beta-blockers and we found that the reduction was more
pronounced in the upright than in the supine position.
Upright CO was also reduced by bisoprolol, and this can be
attributed to the reduction of heart rate since no change in
stroke volume was observed (CO= stroke volume × heart
rate). Subsequently, pharmacological inhibition of the
Fig. 2 Radial systolic (a), radial
diastolic (b), aortic systolic (c),
and aortic diastolic (d) blood
pressure during treatment with
bisoprolol or placebo. Variables
are depicted as mean ± SEM for
every minute of recording. p-
Values represent ANOVA for
repeated measures between
bisoprolol and placebo during
supine (5 min) and upright (5
min) positions. Time interaction
is calculated from the whole 10
min recording period
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increase in heart rate during orthostatic challenge altered the
regulation of SVR, and this variable showed an almost
threefold increase in the upright position when compared
with the response during placebo.
AIx was clearly increased during bisoprolol in the
upright position. The level of AIx is inversely related with
heart rate [28] and directly with SVR [8]. Therefore, the
observed changes in these hemodynamic determinants of
wave reﬂection provide the likely explanation for the
upright increase in AIx during bisoprolol treatment. Fur-
thermore, the increase in aortic PP can be attributed to
enhanced wave reﬂection, as there was no change in the
upright forward wave amplitude during bisoprolol. In
addition, enhanced wave reﬂection also explains the
reduced PP ampliﬁcation in the upright position during
bisoprolol.
Previous studies evaluating the effect of upright posture
on wave reﬂection have suggested that the associated
increase in heart rate may not fully explain the observed
reduction in AIx in non-medicated healthy subjects [13, 29],
and decreased stroke volume could partially explain why
AIx is lower upright than supine. In the present study, no
difference in upright stroke volume was observed between
the bisoprolol and placebo treatments. In addition, the heart-
rate-related variable AIx@75 did not differ during biso-
prolol versus placebo, which emphasizes the signiﬁcance of
heart rate reduction in the observed increase in wave
reﬂection during beta-blockade. An experimental study
using simulated arterial tree proposed that the dependency
of wave reﬂection on heart rate is inﬂuenced by arterial
viscoelasticity [30]. In the study reported here such changes
in arterial viscoelasticity that would only have inﬂuenced
upright hemodynamics seem unlikely. Aortic reservoir
pressure has also been postulated as a variable that inﬂu-
ences the magnitude of the Aix [31–33]. However, the
reservoir pressure concept is not without controversy as the
model has been claimed to diminish the reﬂected waves,
create artefactual waves [34], and even to be based on
incorrect physiological concepts [35].
Pulse wave velocity (PWV) is an important determinant
of AIx since the kinetics of the reﬂected wave depend on the
traveling speed of the pressure wave in the arterial tree [7].
Fig. 3 Heart rate (a), ejection
duration (b), subendocardial
viability ratio (c), and left
cardiac work index (d) during
treatment with bisoprolol or
placebo. Mean ± SEM,
calculations as in Fig. 2
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In our previous report focused on the supine hemodynamics
after bisoprolol, PWV was decreased most likely due to the
parallel reduction in BP [11]. Such a change would favor a
reduction, not an increase, in the level of the AIx. We did
not address PWV during the head-up-tilt, but previous
reports have shown an increase in PWV with upright pos-
ture [36], possibly due to decreased arterial compliance
during the changes in hydrostatic pressure induced by
orthostatic challenge.
The mechanism behind the beta-blockers’ inferior
reduction of cardiovascular events when compared with
vasodilatory antihypertensive drugs is still not completely
understood [1–3]. The CAFÉ-trial showed that despite
similar BP reduction at the brachial level with amlodipine-
based and atenolol-based therapy [4], the BP and PP low-
ering effect at the aortic level was more pronounced with
amlodipine. Higher AIx during atenolol was attributed to the
longer ejection period during slower heart rate, allowing the
peak of the reﬂected pressure wave to augment the central
systolic pressure. This probably has clinical relevance since
central PP has been shown to predict cardiovascular
outcomes better than peripheral PP [37], while this variable
was also associated with cardiovascular endpoints in a post-
hoc analysis of the CAFE trial [4]. Importantly, previous
studies about the hemodynamic effects of beta-blockers have
been exclusively carried out in the supine position and have
rarely included comprehensive evaluation of central BP and
its determinants. To our knowledge, the ﬁnding that upright
posture accentuates the beta-blockers’ deleterious effects on
central BP has not been shown before. Of note, the incidence
of ischemic stroke is highest during morning hours [38], a
moment after waking up and probably after changes in body
posture. The hemodynamic alterations in response to the
changes in body posture might contribute to this circadian
variation and calls for further study in subjects on beta-
blocker therapy.
There are some limitations in this study. The number of
subjects does not allow multivariate analyses to be carried out.
However, the ﬁndings were very clear in this population. The
investigations were done in men only so the results might not
be directly applicable to women. Mathematical transfer func-
tions were required to derive central BP and other
Fig. 4 Stroke volume (a),
cardiac output (b), pulse
pressure ampliﬁcation (c), and
systemic vascular resistance (d)
during treatment with bisoprolol
or placebo. Mean ± SEM,
calculations as in Fig. 2
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hemodynamic variables but good correlation with direct
measurements using these methods has been shown [22].
Bisoprolol decreased peripheral and central BP in men
with grade I to grade II hypertension. However, central
systolic BP was not reduced during head-up tilt. In addition,
the non-beneﬁcial effects on central BP and wave reﬂection
with bisoprolol were especially manifested in the upright
position. These ﬁndings show that central BP regulation is
substantially affected by posture during treatment with beta-
blockers. Altogether, the inﬂuence of posture should be
taken into account when evaluating the effects of anti-
hypertensive agents on hemodynamics.
Summary
What is known about topic
● Beta-blockers do not prevent cardiovascular events to
same extent as other antihypertensive drugs.
● Beta-blockers do not reduce central blood pressure as
well as vasodilatory antihypertensive drugs despite
similar reduction of peripheral blood pressure.
What this study adds
● In supine measurements bisoprolol reduced peripheral
and central blood pressure in never-treated grade I to
grade II hypertensive men with no effect on central
wave reﬂection or central pulse pressure.
● During passive upright tilt, the effect of bisoprolol on
central pulse pressure and wave reﬂection was clearly
detrimental and there was no reduction in central
systolic pressure compared to placebo.
● Hemodynamic measurements performed at rest seem to
underestimate the effect of beta-blocker therapy on the
regulation of hemodynamics as harmful inﬂuences of
bisoprolol on central blood pressure and wave reﬂection
were manifested only during upright tilt.
Fig. 5 Aortic pulse pressure (a),
augmentation index (b), aortic
augmentation pressure (c), and
forward wave amplitude (d)
during treatment with bisoprolol
or placebo. Mean ± SEM,
calculations as in Fig. 2
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